Cabozantinib indications

Cabozantinib is a multi-target small molecule tyrosine kinase inhibitor with the ability to inhibit VEGFR, MET, AXL and other receptors, and can effectively block tumor growth and angiogenesis signaling pathways. With this multi-target mechanism, cabozantinib has shown significant efficacy in the treatment of a variety of solid tumors and has been approved by drug regulatory agencies in many countries for the treatment of multiple cancers.

First, cabozantinib is most commonly used to treat advanced renal cell carcinoma (RCC), especially in patients whose disease has progressed after previously receiving other targeted drugs (such as sunitinib, sorafenib). It not only significantly delays tumor progression but also improves patient survival time. The advantage of cabozantinib in renal cancer is that it can simultaneously inhibit the MET pathway related to drug resistance, so it plays an important role in both first-line and second-line treatment.

Secondly, cabozantinib is also used in the treatment of advanced hepatocellular carcinoma (HCC). Cabozantinib is considered a reliable second-line option for patients whose disease has progressed despite treatment with sorafenib or lenvatinib. Its mechanism is to block the angiogenesis signal of liver cancer cells and slow down the spread of lesions, thereby improving the quality of life and survival rate of patients. Some studies also show that cabozantinib can further enhance its efficacy when combined with immune checkpoint inhibitors (such as PD-1 antibodies).

In addition, cabozantinib is also approved for the treatment of advanced or metastatic medullary thyroid cancer (MTC). This type of cancer is often associated with RET mutations, and cabozantinib can effectively control tumor growth by inhibiting the RET and VEGFR signaling pathways. For patients who are not suitable for surgery or have distant metastasis, oral cabozantinib has become an important treatment method.

At present, the research scope of cabozantinib is still expanding, and some international clinical trials are exploring its application prospects in prostate cancer, lung cancer and soft tissue sarcoma. Its powerful multi-target properties give it unique advantages in the fields of anti-drug resistance mechanisms and combination therapy.

Reference:https://en.wikipedia.org/wiki/Cabozantinib